Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies

Fig. 3

Lipo-EF24 inhibits growth and clonogenicity of pancreatic cancer cell lines. a MTS assays were performed using equivalent doses of free and liposomal EF24 in two different pancreatic cancer cell lines, MIAPaCa and Pa03C. In both cell lines, liposomal EF24 demonstrated marked growth suppression comparable to that of free drug. Further, liposomal EF24 caused significant, dose-dependent reduction in the ability of these cells to form colonies in replating assays (b) and inhibited anchorage-independent growth in soft agar (c). Void liposomes showed no significant effect in any of these cell lines. Representative images from one of three independent experiments are shown

Back to article page